Double-blind, cross-over, international multicentre investigation of two doses of indoprofen compared with ASA and placebo in rheumatoid arthritis.
Indoprofen 600 mg or 1000 mg/day, ASA 3600 mg/day and placebo were administered in randomized sequences according to a multiple 4 x 4 latin square design, balancing the treatments, periods and residual effects. Each treatment lasted 7 days. A total of 98 patients suffering from classical or definite rheumatoid arthritis completed the study. Analysis of the effectiveness indicates that both doses of indoprofen and ASA are significantly more active than placebo; indoprofen 1000 mg/day was the treatment preferred in most of the cases. Both doses of indoprofen were better tolerated than ASA.